Serenno Medical, has developed Sentinel, a device for automatic monitoring and detection of kidney damage in hospitalised patients.
The device is a continuous urine output monitor that measures urine flow rate and volume in real time.
Continuous kidney function assessment allows the early detection of Acute Kidney Injury (AKI), a common condition in hospitalised patients that significantly increases risk of mortality during and after hospitalisation. Accurate measurement of urine output (UO) is clinically accepted as the best method for monitoring kidney function.
Sentinel offers a solution for the measurement of urine flow rate in real time. The system promotes early detection of kidney injury, while there is still time to intervene and prevent further damage. It aims to automatically and accurately detect small changes in kidney function, taking the workload off the nursing staff while delivering actionable data. The device works in synergy with existing hospital equipment (any catheter and bag) and requires a short, non-invasive installation. It fits the complicated intensive care unit (ICU) and operating room environments and is fully functional in any patient condition or hospital environment.
Prof. Manu Malbrain, ICU director, University Hospital Brussels, said: “Urine output measurement is a key parameter to assess kidney function. However, correct urine output determination is often difficult at the bedside and is usually only performed intermittently and manually. Moreover, the kidneys are often the first organ to stop functioning properly, therefore continuous urine output measurement would be a valuable tool in the management of critically ill, unstable patients.”
Serenno Medical recently completed its first multicentre clinical trial with the Sentinel system, showing high reliability and accuracy in a wide range of environments and patient conditions, including low and high urine flow rates, regardless of patient position, during surgical procedures, and including continuous monitoring of patients in a mobile hospital bed. The clinical trial, conducted at three ICU units in Sheba and Rabin Medical centres in Israel, included more than 40 patients and over 1,300 hours of monitoring. Results show over 96% accuracy and reliability.
Shimon Eckhouse, chairman of Serenno Medical, said: “Serenno has developed a unique product that will bring tremendous value to patients hospitalised in ICU units along with a simple digital solution that will bring great economic value to hospitals. Serenno's successful clinical trial is a great testament to the quality and performance of the company's product.”
Tomer Lark, co-founder and CEO of Serenno Medical, added: “The successful results of our first clinical trial will allow the company to move forward to manufacturing the device for commercial usage and enable us to bring this best-in-class product to the global medical markets. We expect to receive FDA clearance for the system during 2020 and believe that our patent pending device has the potential to become the standard-of-care in the OR and ICU, benefiting millions of patients around the world.”
